As the US cannabis industry eagerly awaits the judge’s final recommendation on whether to extend rescheduling, the next phase has already found itself caught in the weeds of bureaucracy.
The US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to VER-01, the flagship full-spectrum cannabis drug from Munich-based Vertanical, putting it in prime position to become the first FDA-approved cannabis-derived medicine for pain, and only the second such approval since Epidiolex in 2018.
After years of false starts, political delays and administrative paralysis, the United States federal government has taken its first concrete step toward rescheduling cannabis.
US Medicare patients have now been given access to cannabidiol (CBD) products through a landmark federal pilot scheme, helping boost cannabis stocks.
Six weeks after the US Food and Drug Administration (FDA) failed to meet its 90-day deadline to clarify which cannabinoids will be impacted by a controversial incoming ban, the White House has scheduled three meetings with industry executives to discuss the matter.
US cannabis rescheduling, much like President Donald Trump who is rightly credited for finally pushing it forward, has sucked all the oxygen out of the room for the last two years.
According to recent analysis from the Congressional Research Service, cannabis businesses may not need to wait for rescheduling to challenge the now-notorious 280E tax burden, suggesting that it may be unconstitutional.
The Food and Drug Administration’s (FDA) 90-day deadline to clarify which cannabinoids will be banned under the incoming, controversial intoxicating hemp ban falls today.
Sorting Evidence from Anecdote As global cannabis research accelerates, the number of published studies has never been higher, but not all evidence carries the same scientific weight.
